상세 보기
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
- Matsubara, Nobuaki;
- de Wit, Ronald;
- Balar, Arjun Vasant;
- Siefker-Radtke, Arlene O.;
- Zolnierek, Jakub;
- ... Park, Se Hoon;
- 외 15명
WEB OF SCIENCE
22SCOPUS
25초록
Background: Pembrolizumab plus lenvatinib has shown antitumor activity and acceptable safety in patients with platinum -refractory urothelial carcinoma (UC). Objective: To evaluate pembrolizumab plus either lenvatinib or placebo as first -line therapy for advanced UC in the phase 3 LEAP -011 study. Design, setting, and participants: Patients with advanced UC who were ineligible for cisplatin-based therapy or any platinum -based chemotherapy were enrolled. Intervention: Patients were randomly assigned (1:1) to pembrolizumab 200 mg intravenously every 3 wk plus either lenvatinib 20 mg or placebo orally once daily. Outcome measurements and statistical analysis: Dual primary endpoints were progression -free survival (PFS) and overall survival (OS). An external data monitoring committee (DMC) regularly reviewed safety and efficacy data every 3 mo. Results and limitations: Between June 25, 2019 and July 21, 2021, 487 patients were allocated to receive lenvatinib plus pembrolizumab (n = 245) or placebo plus pembrolizumab (n = 242). The median time from randomization to the data cutoff date (July 26, 2021) was 12.8 mo (interquartile range, 6.9-19.3). The median PFS was 4.5 mo in the combination arm and 4.0 mo in the pembrolizumab arm (hazard ratio [HR] 0.90 [95% confidence interval {CI} 0.72-1.14]). The median OS was 11.8 mo for the combination arm and 12.9 mo for the pembrolizumab arm (HR 1.14 [95% CI 0.87-1.48]). Grade 3- 5 adverse events attributed to trial treatment occurred in 123 of 241 patients (51%) treated with lenvatinib plus pembrolizumab and in 66 of 242 patients (27%) treated with placebo plus pembrolizumab. This trial was terminated earlier than initially planned based on recommendation from the DMC. Conclusions: The benefit -to -risk ratio for first -line lenvatinib plus pembrolizumab was not considered favorable versus pembrolizumab plus placebo as first -line therapy in patients with advanced UC. Patient summary: Lenvatinib plus pembrolizumab was not more effective than pembrolizumab plus placebo in patients with advanced urothelial carcinoma. (c) 2023 The Authors and Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Published by Elsevier B.V. on behalf of American European Association of Urology.
키워드
- 제목
- Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
- 저자
- Matsubara, Nobuaki; de Wit, Ronald; Balar, Arjun Vasant; Siefker-Radtke, Arlene O.; Zolnierek, Jakub; Csoszi, Tibor; Shin, Sang Joon; Park, Se Hoon; Atduev, Vagif; Gumus, Mahmut; Su, Yu -Li; Karaca, Saziye Burcak; Cutuli, Hernan Javier; Sendur, Mehmet A. N.; Shen, Liji; O'Hara, Karen; Okpara, Chinyere E.; Franco, Sonia; Moreno, Blanca Homet; Grivas, Petros; Loriot, Yohann
- 발행일
- 2024-03
- 유형
- Article
- 저널명
- European Urology
- 권
- 85
- 호
- 3
- 페이지
- 229 ~ 238
- 언어
- ENG
- 출판사
- Elsevier BV
- 발행국가
- 네덜란드
- 분량
- 10 페이지
- ISSN
- E 1873-7560
P 0302-2838